Victoria Y. Ding

Victoria Y. Ding

Auto-generated profile, based on publicly available information

Victoria Y. Ding

Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
WFWilliam F. Fearon
William F. Fearon
FZFrederik M. Zimmermann
Frederik M. Zimmermann
BBBernard De Bruyne
Bernard De Bruyne
ZPZsolt Piroth
Zsolt Piroth
ASAlbert H.M. van Straten
Albert H.M. van Straten
NPNico H.J. Pijls
Nico H.J. Pijls
Patients with three-vessel coronary artery disease have been found to have better outcomes with coronary-artery bypass grafting (CABG) than with percutaneous coronary intervention (PCI), but studies in which PCI is guided by measurement of fractional flow reserve (FFR) have been lacking.

19 September 2023 in Circulation
Verified
Journal Article
Closed access
FZFrederik M. Zimmermann
Frederik M. Zimmermann
VDVictoria Y. Ding
Victoria Y. Ding
NPNico H.J. Pijls
Nico H.J. Pijls
Zsolt PiróthZsolt Piróth
Zsolt Piróth
ASAlbert H.M. van Straten
Albert H.M. van Straten
OIon behalf of the FAME 3 Investigators
on behalf of the FAME 3 Investigators
BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83]; P =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7]; P =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7]; P =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1–2.7]; P =0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02100722.

3 May 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PPPriya Prahalad
Priya Prahalad
DSDavid Scheinker
David Scheinker
MDManisha Desai
Manisha Desai
VDVictoria Y. Ding
Victoria Y. Ding
FBFranziska K. Bishop
Franziska K. Bishop
DMDavid M. Maahs
David M. Maahs

13 November 2020 in Journal of Computer Assisted Tomography
Verified
Journal Article
Open access
FKFrans Kauw
Frans Kauw
JDJan Willem Dankbaar
Jan Willem Dankbaar
BMBlake W. Bs Martin
Blake W. Bs Martin
VDVictoria Y. Ding
Victoria Y. Ding
DBDerek B. Boothroyd
Derek B. Boothroyd
MWMax Wintermark
Max Wintermark
Objective: To compare assessment of collaterals by single-phase computed tomography (CT) angiography (CTA) and CT perfusion-derived 3-phase CTA, multiphase CTA and temporal maximum-intensity projection (tMIP) images to digital subtraction angiography (DSA), and relate collateral assessments to clinical outcome in patients with acute ischemic stroke. Methods: Consecutive acute ischemic stroke patients who underwent CT perfusion, CTA, and DSA before thrombectomy with occlusion of the internal carotid artery, the M1 or the M2 segments were included. Two observers assessed all CT images and one separate observer assessed DSA (reference standard) with static and dynamic (modified American Society of Interventional and Therapeutic Neuroradiology) collateral grading methods. Interobserver agreement and concordance were quantified with Cohen-weighted κ and concordance correlation coefficient, respectively. Imaging assessments were related to clinical outcome (modified Rankin Scale, ≤ 2). Results: Interobserver agreement (n = 101) was 0.46 (tMIP), 0.58 (3-phase CTA), 0.67 (multiphase CTA), and 0.69 (single-phase CTA) for static assessments and 0.52 (3-phase CTA) and 0.54 (multiphase CTA) for dynamic assessments. Concordance correlation coefficient (n = 80) was 0.08 (3-phase CTA), 0.09 (single-phase CTA), and 0.23 (multiphase CTA) for static assessments and 0.10 (3-phase CTA) and 0.27 (multiphase CTA) for dynamic assessments. Higher static collateral scores on multiphase CTA (odds ratio [OR], 1.7; 95% confidence interval [CI], 1.1–2.7) and tMIP images (OR, 2.0; 95% CI, 1.1–3.4) were associated with modified Rankin Scale of 2 or less as were higher modified American Society of Interventional and Therapeutic Neuroradiology scores on 3-phase CTA (OR, 1.5; 95% CI, 1.1–2.2) and multiphase CTA (OR, 1.7; 95% CI, 1.1–2.6). Conclusions: Concordance between assessments on CT and DSA was poor. Collateral status evaluated on 3-phase CTA and multiphase CTA, but not on DSA, was associated with clinical outcome.

7 January 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
BJB. Jiang
B. Jiang
GZG. Zhu
G. Zhu
YXY. Xie
Y. Xie
JHJ.J. Heit
J.J. Heit
HCH. Chen
H. Chen
MWMax Wintermark
Max Wintermark
BACKGROUND AND PURPOSE: Traditional statistical models and pretreatment scoring systems have been used to predict the outcome for acute ischemic stroke patients (AIS). Our aim was to select the most relevant features in terms of outcome prediction on the basis of machine learning algorithms for patients with acute ischemic stroke and to compare the performance between multiple models and the Stroke Prognostication Using Age and National Institutes of Health Stroke Scale (SPAN-100) index model. MATERIALS AND METHODS: A retrospective multicenter cohort of 1431 patients with acute ischemic stroke was subdivided into recanalized and nonrecanalized patients. Extreme Gradient Boosting machine learning models were built to predict the mRS score at 90 days using clinical, imaging, combined, and best-performing features. Feature selection was performed using the relative weight and frequency of occurrence in the models. The model with the best performance was compared with the SPAN-100 index model using area under the receiver operating curve analysis. RESULTS: In 3 groups of patients, the baseline NIHSS was the most significant predictor of outcome among all the parameters, with relative weights of 0.36∼0.69; ischemic core volume on CTP ranked as the most important imaging biomarker with relative weights of 0.29∼0.47. The model with the best-performing features had a better performance than the other machine learning models. The area under the curve of the model with the best-performing features was higher than SPAN-100 model and reached statistical significance for the total (P < .05) and the nonrecanalized patients (P < .001). CONCLUSIONS: Machine learning–based feature selection can identify parameters with higher performance in outcome prediction. Machine learning models with the best-performing features, especially advanced CTP data, had superior performance of the recovery outcome prediction for patients with stroke at admission in comparison with SPAN-100.

13 September 2022 in Diabetology
Verified
Journal Article
Open access
PDF file
DZDessi Zaharieva
Dessi Zaharieva
AAAnanta Addala
Ananta Addala
PPPriya Prahalad
Priya Prahalad
BLBrianna Leverenz
Brianna Leverenz
NANora Arrizon-Ruiz
Nora Arrizon-Ruiz
DMDavid M. Maahs
David M. Maahs
During the COVID-19 pandemic, fewer in-person clinic visits resulted in fewer point-of-care (POC) HbA1c measurements. In this sub-study, we assessed the performance of alternative glycemic measures that can be obtained remotely, such as HbA1c home kits and Glucose Management Indicator (GMI) values from Dexcom Clarity. Home kit HbA1c (n = 99), GMI, (n = 88), and POC HbA1c (n = 32) were collected from youth with T1D (age 9.7 ± 4.6 years). Bland–Altman analyses and Lin’s concordance correlation coefficient (𝜌c) were used to characterize the agreement between paired HbA1c measures. Both the HbA1c home kit and GMI showed a slight positive bias (mean difference 0.18% and 0.34%, respectively) and strong concordance with POC HbA1c (𝜌c = 0.982 [0.965, 0.991] and 0.823 [0.686, 0.904], respectively). GMI showed a slight positive bias (mean difference 0.28%) and fair concordance (𝜌c = 0.750 [0.658, 0.820]) to the HbA1c home kit. In conclusion, the strong concordance of GMI and home kits to POC A1c measures suggest their utility in telehealth visits assessments. Although these are not candidates for replacement, these measures can facilitate telehealth visits, particularly in the context of other POC HbA1c measurements from an individual.